CRITICAL VIEW OF EFFICACY ANTIANGIOGENIC THERAPY IN ONCOLOGY

Bevacizumab was the first antiangiogenic targeted drug, which was approved in 2004 in metastatic colorectal cancer patients. During the next 14 years antiangiogenic therapy became the integral part of the routine clinical practice for the treatment of several cancers. However, for these years the conception of the anticancer activity of antiangiogenic drugs was changed, a lot of study with negative result was published as for metastatic cancer and adjuvant settings. Several mechanisms of resistance for antiangiogenic therapy were discovered. All these data demand of detailed critical investigation for determination of genuine opportunities and perspectives of antiangiogenic therapy in oncology.